T3 Pharmaceuticals AG

T3 Pharmaceuticals AG

Biotechnologieforschung

Basel, BS 3.278 Follower:innen

Developing the next generation bacterial cancer therapy

Folgen

Info

Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria. T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of live bacteria. While the technology has diverse applications in research, T3 Pharma has further developed the system to serve as a novel therapeutic to treat solid tumors.

Website
http://www.t3pharma.com
Branche
Biotechnologieforschung
Größe
11–50 Beschäftigte
Hauptsitz
Basel, BS
Kunst
Privatunternehmen
Gegründet
2015
Spezialgebiete
Biotechnology, Cancer therapy, Protein delivery und Bacterial cancer therapy

Orte

  • Primär

    c/o Biozentrum, Universität Basel

    Klingelbergstr. 50/70

    Basel, BS 4056, CH

    Wegbeschreibung

Beschäftigte von T3 Pharmaceuticals AG

Alle Beschäftigten anzeigen

Aktualisierungen

Ähnliche Seiten